Latest news with #Eligo
Globe and Mail
6 days ago
- Business
- Globe and Mail
Eligo eVoting Launches Low-Coercion and Verifiable Digital Voting Protocol in the U.S.
Eligo eVoting announces the U.S. release of its secure digital voting protocol, designed with low coercion and end-to-end verifiability to ensure transparency and voter autonomy across private and public organizations. Eligo eVoting has announced the U.S. launch of its secure digital voting protocol, built on the principles of low coercion and end-to-end verifiability (E2E-VIV). The platform ensures privacy, eliminates vote manipulation, and reinforces trust without requiring a central scrutiny authority. This next-generation solution is already used by leading multinational corporations, trade unions, universities, and public institutions across Europe and Latin America. Now, Eligo aims to empower U.S. organizations, both public and private, with a system that guarantees voter autonomy and result integrity from start to finish. A new era of transparent voting Traditional digital voting systems often rely on internal oversight to verify accuracy and trustworthiness. Eligo's innovative online voting system removes that dependency through a self-verifying cryptographic framework. Its end-to-end verifiable architecture allows voters to independently confirm that their vote was cast as intended, recorded as cast, and counted as recorded, all while preserving complete anonymity. At the same time, the system incorporates low coercion protocols to minimize the risk of undue influence during the voting process. This ensures that votes are not only secure, but genuinely free expressions of the voter's will, even in remote or hybrid voting environments. 'We developed this protocol to help organizations run secure, independent, and transparent elections,' said Irene Pugliatti, CEO of Eligo eVoting. 'By combining low coercion with end-to-end verifiability, we're supporting confidence in digital voting processes worldwide.' Security without complexity What sets Eligo apart is its ability to combine state-of-the-art online voting security with a user-friendly interface. From online board elections and union votes to general assemblies and referendums, the platform is fully customizable and ready to scale for elections of any size or complexity. The newly released E2E-VIV protocol, developed by the University of Warwick, is based on a variant of the DRE-ip protocol to provide E2E verifiability with support for low coercion mitigation (revoting capability). Eligo system still supports digital signature and timestamping to ensure immutability of all reports according to PADES standard. Furthermore, Eligo adheres to strict international standards, including ISO/IEC 27001 for information security and ISO 9001 for quality management, reinforcing its commitment to data protection and process excellence. A growing footprint in the Americas Eligo's arrival in the U.S. follows a string of successful implementations across Latin America, including high-impact elections for professional associations, national trade unions, and universities in Mexico, Chile, and Colombia. Its presence in the Americas is rapidly expanding as organizations seek digital solutions that offer both flexibility and institutional-grade reliability. The U.S. market represents a key milestone in Eligo's global expansion strategy. With growing demand for modern governance tools, especially in hybrid work environments and increasingly digital civic engagement, the company sees strong alignment between its technological values and the expectations of American institutions. Experience real transparency Eligo is inviting U.S.-based organizations, from corporations to municipalities, from associations to academic institutions, to experience the platform in action. Live demos are now available upon request, allowing stakeholders to test drive the system and explore its secure, verifiable features. Book a live online voting demo to explore how Eligo's online voting software supports transparent and verifiable digital voting for public and private organizations. About Eligo eVoting Founded in Milan and operating across Europe and Latin America, Eligo eVoting is a digital voting platform designed to modernize the way organizations vote. With a focus on transparency, security, and usability, Eligo has enabled over 10,000 secure elections globally for companies, associations, unions, universities, and public bodies. The platform supports multiple voting methods, complies with international data protection regulations, and now offers a fully end-to-end verifiable protocol with low coercion safeguards for the U.S. market. Media Contact Company Name: Eligo Contact Person: Irene Pugliatti Email: Send Email Country: Italy Website:
Korea Herald
13-05-2025
- Business
- Korea Herald
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
PARIS, May 13, 2025 /PRNewswire/ -- Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 million grant from the French government to accelerate the advancement and scaling up of Eligo's proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria. This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline. Scaling up and advancing towards the clinic Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose's extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo's progress toward clinical validation. "This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications," said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience."It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide." Expansion to immuno-dermatology targets The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells. Eligo's unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs. The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.
Cision Canada
13-05-2025
- Business
- Cision Canada
Eligo Bioscience Awarded $5 Million to Advance Breakthrough Genetic Medicine Platform for Immuno-Dermatology
Funding is part of the call for proposals "Innovations in Biotherapies and Bioproduction," coordinated by the Health Innovation Agency under France 2030 strategy, operated on behalf of the French government by Bpifrance PARIS, May 13, 2025 /CNW/ -- Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 million grant from the French government to accelerate the advancement and scaling up of Eligo's proprietary topical gene delivery platform, designed to enable local production of therapeutic biologics directly by skin-resident bacteria. This grant follows recent key milestones for Eligo, including the publication of its microbiome base-editing platform in Nature, securing multiple foundational patents covering in situ editing of the skin microbiome, and successfully expanding its Series B funding round to $35 million. This latest non-dilutive financial support strengthens Eligo's capacity to rapidly advance its clinical pipeline. Scaling up and advancing towards the clinic Building on the development of its first-generation CRISPR-based topical therapeutic targeting moderate to severe acne vulgaris, Eligo will now optimize and scale up the bioproduction process of its innovative gene delivery vector ahead of later-stage clinical trials. In this endeavor, Eligo is partnering with Biose Industries, a globally recognized CDMO specializing in microbial fermentation. Biose's extensive GMP expertise in scaling complex microbial therapeutics will be instrumental in accelerating Eligo's progress toward clinical validation. "This funding empowers us to establish a robust bioproduction process for our first-in-class topical microbiome-targeting gene-editing therapies, laying the groundwork for expanding into a wide range of immuno-dermatological indications," said Dr. Xavier Duportet, CEO and Co-Founder of Eligo Bioscience."It reinforces our ambition to deliver truly transformative therapeutic solutions, addressing critical medical challenges faced by millions of patients worldwide." Expansion to immuno-dermatology targets The skin microbiome plays a pivotal role in cutaneous immune regulation, and commensal bacteria residing within the hair follicle lie in immediate proximity to resident immune cells. Eligo's unique in-situ delivery modality enables to perform in-situ genetic engineering of these commensal bacteria, turning them as localized bioreactors that can express high-potency biologics precisely where immune dysregulation occurs. The new funding will support the exploration of multiple therapeutic payloads and the build-out of a diversified immuno-dermatology pipeline targeting chronic inflammatory and immune-mediated skin diseases with significant unmet need.
